| abstract |
The present invention relates to a novel fusion protein vaccine against urinary tract-infected E. coli, and more particularly, to genes encoding antigenic determinants of urea-infected E. coli, and to increase mucosal immunity and act as an adjuvant ( Vibrio). cholerae ) and non-toxic toxin gene CTXA2B and non-toxic toxin-like gene LTXA2B of heat-labile E. coli enterotoxin, and the recombinant gene is expressed, isolated and purified from E. coli It is about a fusion protein that can be used as a vaccine against.n n n According to the present invention of the above-described configuration, it is expected to significantly reduce recurrent urinary tract infection because it is possible to obtain an oral vaccine having a low side effect and excellent effect, and also prevents the emergence of resistant bacteria due to the abuse of antibiotics, It is expected to significantly reduce the dependence on chemotherapeutic agents. In addition, it can be commercialized and commercialized in a short time at low cost, and it is believed that it is possible to acquire flexible technology for application to various vaccines by easily changing the components. |